Key Highlights
- Second-quarter revenue reached £8.41 billion, surpassing analyst estimates of £8.24 billion
- Core earnings per share of 50.5 pence exceeded the 47.1 pence projection
- Specialty Medicines segment grew 14%, Vaccines division increased 8%; General Medicines declined 9%
- Company unveiled a £1.9 billion ($2.52 billion) efficiency program spanning three years
- 2026 annual guidance maintained, with revenue growth projected at the top end of 3%–5% range
Shares of GSK surged 4.2% on Tuesday following the British pharmaceutical company’s second-quarter financial report that exceeded Wall Street projections and the unveiling of a significant efficiency initiative.
The company’s second-quarter revenue totaled £8.41 billion, surpassing the analyst consensus of £8.24 billion. Core operating profit reached £2.80 billion, exceeding the £2.68 billion projection.
Pre-tax core profit climbed to £2.68 billion, beating the £2.52 billion estimate. Core earnings per share of 50.5 pence outperformed the analyst consensus of 47.1 pence.
The pharmaceutical company announced a quarterly dividend of 17 pence per share, matching market expectations.
The Specialty Medicines division led performance metrics, with revenue increasing 14% to £3.8 billion. The Oncology segment expanded 17% while HIV treatments rose 10%.
The Vaccines division generated £2.3 billion in revenue, marking an 8% increase. Shingrix contributed £0.9 billion, representing a 3% gain, while Meningitis product sales more than doubled to £0.2 billion.
However, some segments faced headwinds. General Medicines revenue declined 9% to £2.3 billion. Trelegy sales decreased 7% to £0.8 billion.
$2.5 Billion Efficiency Initiative
In conjunction with its earnings report, GSK introduced a £1.9 billion ($2.52 billion) efficiency program spanning three years. The initiative aims to generate capital for financing advanced-stage pharmaceutical development.
Chief Executive Officer Luke Miels stated the program will “simplify the organisation and reallocate capital and resources” to bolster the late-stage development pipeline.
The cost reductions will partially finance Miels’ strategy for accelerated drug development — a critical objective as the company confronts impending patent expirations on multiple products.
Research and Domestic Investment
GSK also announced a £400 million investment in the United Kingdom, featuring a new research and development facility. The commitment reinforces Miels’ broader strategy to strengthen the company’s product pipeline.
The pharmaceutical giant has pursued an aggressive acquisition strategy. In June, it finalized its largest acquisition to date — the purchase of Nuvalent — as part of its oncology portfolio expansion.
The organization has established a target of achieving over £40 billion in annual revenue by 2031. Upcoming patent expirations represent a significant challenge to reaching that milestone.
GSK maintained its 2026 full-year outlook, now indicating revenue growth at the higher end of its 3%–5% projected range.
Shares traded 4.2% higher at 1120 GMT on Tuesday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
